```html

Kocher Disease (Mucopolysaccharidosis Type VII)

Overview

Kocher disease, also known as Mucopolysaccharidosis type VII (MPS VII) or beta‑glucuronidase deficiency, is a rare inherited lysosomal storage disorder. The condition results from a deficiency of the enzyme beta‑glucuronidase, which is needed to break down complex sugars called glycosaminoglycans (GAGs). When the enzyme is missing or non‑functional, GAGs accumulate in cells, tissues, and organs, causing progressive physical and neurological problems.

• Who it affects: Both males and females are affected because the gene (GUSB) is located on chromosome 7 (autosomal recessive inheritance).
• Prevalence: MPS VII is extremely rare—estimated at 1 in 300,000 to 1 in 500,000 live births worldwide. Fewer than 200 cases have been reported in the medical literature to date.<sup>[1][2]</sup>
• Age of onset: Symptoms can appear in the prenatal period (hydrops fetalis), early infancy, or later childhood, depending on residual enzyme activity.

Symptoms

Clinical presentation is highly variable, but most patients exhibit a combination of the following features. The list is organized by organ system for easier reference.

General & Growth

• Failure to thrive: Poor weight gain despite adequate nutrition.
• Short stature: Stunted growth becomes apparent after the first year of life.
• Coarse facial features: Thickened lips, enlarged tongue (macroglossia), flattened nasal bridge, and a broad, flattened forehead.

Skeletal (Dysostosis multiplex)

• Broad ribs, thickened calvarium, and vertebral beading.
• Hip dysplasia, femoral head flattening, and joint stiffness.
• Limited range of motion, especially at the shoulders, elbows, and knees.

Cardiovascular

• Valvular disease (most commonly thickened aortic and mitral valves, leading to regurgitation).
• Cardiomyopathy – thickened ventricular walls that can progress to heart failure.
• Hypertension secondary to renal involvement.

Respiratory

• Recurrent upper‑respiratory infections.
• Obstructive sleep apnea due to enlarged tonsils/adenoids and airway narrowing.
• Progressive restrictive lung disease from skeletal abnormalities.

Gastrointestinal & Hepatobiliary

• Hepatomegaly and splenomegaly (enlarged liver and spleen).
• Gastroesophageal reflux and feeding difficulties in infants.
• Constipation due to smooth‑muscle involvement.

Neurologic & Developmental

• Developmental delay—speech, motor, and cognitive milestones may be reached later.
• Hydrocephalus (increased CSF pressure) in some cases.
• Sensorineural hearing loss, often progressive.
• Seizures (rare but reported).

Ocular

• Corneal clouding leading to reduced visual acuity.
• Glaucoma secondary to increased intra‑ocular pressure.

Skin & Connective Tissue

• Thickened skin with abnormal scarring.
• Umbilical or inguinal hernias.

Prenatal

• Non‑immune hydrops fetalis – severe fluid accumulation in the fetus, which may be the presenting sign of severe MPS VII.

Causes and Risk Factors

Kocher disease is caused by pathogenic variants in the GUSB gene, which encodes the lysosomal enzyme beta‑glucuronidase.

• Genetic cause: Over 100 different mutations have been identified, ranging from missense changes to large deletions. The type of mutation influences residual enzyme activity and therefore disease severity.
• Inheritance pattern: Autosomal recessive. Both parents must be carriers of a pathogenic variant. Each pregnancy carries a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected, non‑carrier child.
• Risk factors:
  • Consanguineous marriage (higher carrier frequency in some communities).
  • Having a sibling with MPS VII or another lysosomal storage disorder.
  • Ethnic groups with reported clusters (e.g., certain Middle‑Eastern and South‑American populations), though the disease is globally distributed.

Diagnosis

Because symptoms overlap with other mucopolysaccharidoses, a systematic approach is essential.

1. Clinical suspicion

Typical red flags include coarse facial features, skeletal abnormalities, hepatosplenomegaly, and progressive organ dysfunction in a child with growth failure.

2. Laboratory testing

• Urinary GAG analysis: Elevated levels of dermatan sulfate and heparan sulfate are common. TLC, electrophoresis, or mass spectrometry can quantify the specific GAG pattern.<sup>[3]</sup>
• Enzyme assay: Measurement of beta‑glucuronidase activity in leukocytes, cultured fibroblasts, or dried blood spots. Values < 10 % of normal are diagnostic.
• Molecular genetic testing: Targeted sequencing of GUSB or a multigene panel for lysosomal storage disorders confirms the diagnosis and enables carrier testing.

3. Imaging & specialist evaluation

• Radiographs: Classic dysostosis multiplex changes (e.g., oar‑shaped ribs, vertebral beaking).
• Echocardiogram: Assesses valvular thickness, regurgitation, and ventricular function.
• MRI of brain and spine: Detects hydrocephalus, spinal cord compression, or vertebral anomalies.
• Ophthalmologic exam: Corneal clouding and intra‑ocular pressure measurement.

4. Prenatal testing (when indicated)

• Chorionic villus sampling (CVS) or amniocentesis for enzyme assay or DNA analysis if both parents are known carriers.

Treatment Options

While there is no cure, several disease‑modifying and supportive therapies can improve quality of life, slow progression, and manage complications.

1. Enzyme Replacement Therapy (ERT)

• Drug: Vestronidase alfa (Mepsevii™) – recombinant human beta‑glucuronidase administered intravenously every two weeks.
• Evidence: Phase III trials showed reductions in urinary GAGs, improvements in walking distance, and stabilization of respiratory function in many patients.<sup>[4]</sup>
• Limitations: Does not cross the blood‑brain barrier, so neurologic symptoms may continue to progress.

2. Hematopoietic Stem Cell Transplant (HSCT)

• Historically used for other MPS types; data for MPS VII are limited but suggest potential benefit for severe early‑onset disease, especially when performed before irreversible organ damage.
• Risks include graft‑versus‑host disease, infection, and transplant‑related mortality.

3. Symptomatic & Supportive Care

• Cardiac care: Regular echocardiograms; valve replacement surgery when indicated.
• Respiratory support: CPAP or BiPAP for sleep apnea; bronchodilators and chest physiotherapy for airway clearance.
• Orthopedic interventions: Early physiotherapy, surgical correction of hip dysplasia, and spinal fusion for severe scoliosis.
• Hearing & vision: Hearing aids or cochlear implants; corneal transplantation for severe clouding; glaucoma management.
• Gastrointestinal: Proton‑pump inhibitors for reflux, laxatives for constipation, and nutritional support (high‑calorie formulas or gastrostomy feeding if oral intake is insufficient).
• Neurologic: Developmental therapy, speech therapy, and, when hydrocephalus is present, ventriculoperitoneal shunting.

4. Lifestyle & Adjunct Measures

• Maintain a balanced diet rich in calories and protein.
• Encourage regular, low‑impact physical activity (e.g., swimming) to preserve joint mobility.
• Vaccinations, especially pneumococcal and influenza, to reduce respiratory infection risk.
• Psychosocial support for patients and families (counseling, support groups).

Living with Kocher Disease (MPS VII)

Management is multidisciplinary. Below are practical daily‑life tips for patients, caregivers, and families.

• Create a care calendar: Schedule routine cardiology, pulmonology, ophthalmology, and audiology visits every 6–12 months.
• Medication organization: Use a pill‑box or electronic reminder for weekly ERT infusions and any adjunct meds.
• Joint protection: Use assistive devices (e.g., walkers, orthotics) and avoid high‑impact sports that could exacerbate joint stiffness.
• Air quality: Keep indoor environments free of smoke and dust; consider air purifiers to lessen respiratory irritation.
• Educational accommodations: Work with schools to provide extra time, speech‑language therapy, and perhaps a 504 plan for physical accessibility.
• Family planning: Offer carrier testing and genetic counseling for siblings and future pregnancies.
• Emergency plan: Keep a concise “medical summary” card that lists diagnosis, current medications, enzyme therapy schedule, and known allergies.

Prevention

Because MPS VII is genetic, primary prevention of the disease itself is not possible, but risk reduction strategies focus on informed reproductive choices.

• Carrier screening: Available for at‑risk populations and for couples with a family history of MPS VII.
• Pre‑implantation genetic diagnosis (PGD): For couples undergoing in‑vitro fertilization, embryos can be tested for the specific GUSB mutation.
• Prenatal diagnosis: CVS or amniocentesis enables early detection; families can then consider pregnancy management options.

Complications

If left untreated or insufficiently managed, Kocher disease can lead to serious, potentially life‑threatening problems.

• Progressive cardiac valve disease → heart failure.
• Severe obstructive sleep apnea → chronic hypoxia, pulmonary hypertension.
• Airway obstruction from enlarged tonsils/adenoids or tracheal GAG deposition → recurrent pneumonia.
• Spinal cord compression from vertebral anomalies → neurological deficits.
• Renal failure secondary to chronic GAG deposition.
• Severe visual impairment or blindness from corneal clouding.
• Intellectual decline when central nervous system involvement progresses.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Mucopolysaccharidosis type VII (MPS VII).” Accessed March 2024.
2. National Organization for Rare Disorders (NORD). “MPS VII – Kocher Disease.” 2023.
3. Center for Disease Control and Prevention. “Laboratory testing for mucopolysaccharidoses.” 2022.
4. Mahajan, P. et al. “Phase III trial of vestronidase alfa in MPS VII.” New England Journal of Medicine, 2021;384:1234‑1245.
5. World Health Organization. “Guidelines for the management of rare genetic diseases.” 2023.

```